Fig. 6: Efficacy of ICVB-1042 in human tumor xenograft mouse models.

a Efficacy of IV or IT administration of ICVB-1042 was evaluated using various human tumor xenograft models in NSG mice (subcutaneous or orthotopic). Tumor growth inhibition by ICVB-1042 was evaluated by calculating the delta treatment (ΔT)/delta control (ΔC) ratio. Note that PC-3 tumor growth inhibition was determined based on measurements with bioluminescent imaging (BLI) rather than caliper measurements. In all models, mice previously implanted with tumors were treated with three administrations of ICVB-1042 or vehicle IV or IT on days 0, 3, and 6. TGI graphs and overall survival for each model can be found in Supplementary Fig. 11. b–d NSG, female mice bearing orthotopic human breast carcinoma tumors (6–7 weeks old at implant) were treated IV with ICVB-1042 (red) or Wt Ad5 (blue) (2.00E8 PFU), or vehicle, on day 0, 3, and 6. b Mean tumor volume, represented by solid lines (n = 5 animals per group). Data has been excluded when less than 50% of animals were alive. Statistical test with One-way ANOVA followed by a post-hoc pairwise comparison (Holm–Sidak) on Day 28 post the first ICVB-1042 administration indicated a significant (p < 0.05) difference between ICVB-1042 and Wt Ad5. c Viral genome copies per ng DNA recovered. d Viral genome copy concentrations per µL of plasma.